Podcasts about Case Western Reserve University

Seen TikTok videos about taking "just a little bit" of Ozempic or counting pen clicks instead of using the prescribed dose? That's microdosing, and it's showing up everywhere—from social media to patient discussions. In this episode, I will cut through the hype to explain what microdosing GLP-1 medications really means, why people are trying it (spoiler: cost and side effects), and what the research actually says. I will discuss the concept of "super responders" who seem to do well on lower doses, the lack of scientific backing for DIY microdosing, and the real risks of using compounded or diluted versions of these medications. Tune in to learn why working with your healthcare provider is essential for safe, effective dosing—and discover legitimate ways to manage side effects and costs without compromising your results.   Episode Highlights: What microdosing GLP-1s actually means The difference between super responders and unsafe microdosing Why professional organizations don't endorse microdosing Hidden risks of compounded and diluted medications Safe alternatives for managing side effects and medication costs   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

The goal of these episodes is to go over the most cited articles in a certain topic over the past 15-20 years to give learners an idea of what articles are being read and what are some of the important studies out there to read! In this episode we have Dr. Samuel Fuller, a resident at University at Buffalo, Dr. Alexander Macfarlane, a current shoulder & Elbow fellow, Teja Polisetty, a resident at Harvard University, Brad Hawayek, a resident at the University of Buffalo, Matthew Corsi, a resident at Corewell East/Beaumont RO, Jalen Warren, a resident at Case Western Reserve University, and Matthew Alben, a resident at University at Buffalo. They discuss SLAP Tears. Enjoy!  Ortho Essentials 101: The #1 prep course for orthopaedic surgery rotations and intern year. Join over 100 others and learn Orthopaedics! courses.naileditortho.com

Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today's biotech macro headwinds and building companies that can translate breakthrough science into real patient impact. Dr. Duyk traces his journey from Harvard/Millennium/Exelixis operator to TPG investor and back to company creation, explaining how board dynamics, capital cycles, and policy shifts shape execution. They dig into why this cycle feels uniquely tough—patent cliffs, reimbursement uncertainty, NIH pressures—and who funds innovation in the meantime. Duyk outlines root causes of R&D inefficiency (misaligned capital vs. 20-year timelines, shaky preclinical predictability, costly trials, underused real-world data) and makes the case for rebuilding public trust and STEM education. Then, a deep dive on Grove Biopharma: precision polymer science that creates antibody-like, fully synthetic, cell-permeable protein mimetics to tackle historically “intractable” intracellular protein–protein interactions. Duyk shares design principles, why modular/orthogonal chemistry matters, predictable pharmacology, and lessons from fundraising and board management—plus why he's helping grow a Chicago-centered biotech ecosystem. Biography: Geoffrey M. Duyk, M.D., Ph.D. is the Chief Executive Officer of Grove Biopharma. Dr. Duyk has spent 30 years in the biotechnology industry as an entrepreneur, executive, and investor. Most recently, he was the Managing Partner at Circularis Partners, an investment firm he co-founded, focused on advancing the circular economy and promoting sustainability. Prior to that, Dr. Duyk was Managing Director and Partner at TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology. Before joining TPG, Dr. Duyk served as a board member and President of R&D at Exelixis and was one of the founding scientific staff members at Millennium Pharmaceuticals, where he served as Vice President of Genomics. Earlier in his career, Dr. Duyk was an Assistant Professor in the Department of Genetics at Harvard Medical School (HMS) and an Assistant Investigator at the Howard Hughes Medical Institute (HHMI). While at HMS, he served as a co–principal investigator in the Cooperative Human Linkage Center, which was funded by the National Institutes of Health (NIH). Dr. Duyk is a trustee of Case Western Reserve University, where he serves on the executive committee. He previously served on the Board of Trustees of Wesleyan University and the Board of Directors of the Moffitt Cancer Center. He currently serves on the IR&E (Institutional Research and Evaluation) Committee at Moffitt, a key component of its External Advisory Committee (EAC). He was also a member of the Board of Directors of the American Society of Human Genetics (ASHG), and served as its treasurer. He is a member of the Life Sciences Advisory Board at Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Laboratory (DOE). Dr. Duyk previously served on the board of the Jackson Laboratory and on numerous NIH advisory committees. He is currently a Senior Advisor at Qiming Venture Partners (USA) and serves on the boards of Enno DC, Oobli, and Melanyze Dr. Duyk earned both his M.D. and Ph.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a Lucille P. Markey Fellow and an HHMI postdoctoral fellow. He is a fellow of the American Association for the Advancement of Science.

This week we revisit our interview Joe Mandato. Joe holds a Doctor of Business Administration degree from Case Western Reserve University, where his research focused on the evolving role of boards in ensuring effective corporate governance.  He was a 2011-2012 Fellow of Harvard University's Advanced Leadership Initiative and served as Co-Chair of Harvard's Advanced Leadership Coalition. He is a Managing Director at DeNovo Ventures, Senior Advisor at Apercen Partners, Advisor to Sonder Capital, and 15-year Lecturer at Stanford University.   He has served on more than 20 public and private boards focused on technology and the life sciences, including Align Technology (NASDAQ), Avedro, Axogen, Inc. (NASDAQ), Hansen Medical (NASDAQ), Insound Medical & Vynca Health.  He also serves on the boards of Case Western Reserve University, Headstart, and Save the Children.   He was a seed investor, board member and advisor to the founders of Align Technologies and has served as CEO of five life sciences companies, which resulted in significant shareholder value.  He was a member of the founding management committee of Guidant Corporation (NYSE) and was an entrepreneur-in-residence at Mayfield Fund, a Silicon Valley venture fund.  He has authored or co-authored thirty articles on healthcare and governance and the book The Entrepreneur's Journey.

Joseph diGenova, former U.S. Attorney for the District of ColumbiaTopic: Letitia James indictment 7:25- Col. Jack Jacobs, a retired colonel in the United States Army and a Medal of Honor recipient for his actions during the Vietnam WarTopic: Logistics of the Israel-Hamas peace deal Louis Tallarini, President of Real Property Investors, Inc.Topic: Italian American Heritage Month Liz Peek, Fox News contributor, columnist for Fox News and The Hill, and former partner of major bracket Wall Street firm Wertheim & CompanyTopic: "The ‘Schumer shutdown’ could be Trump's best chance to drain the swamp" (Fox News op ed) Corey Lewandowski, Trump 2024 Senior OfficialTopic: Trump's cabinet meeting, Israel-Hamas peace deal, other White House news Anat Alon-Beck, corporate law professor at Case Western Reserve University and a visiting scholar at Harvard Law SchoolTopic: "I nominated President Trump for the Nobel Peace Prize — here's why he deserves it" (Fox News op ed) Lee Zeldin, Administrator of the Environmental Protection AgencyTopic: Trump cabinet meeting David Friedman, Former U.S. Ambassador to Israel and the author of "Sledgehammer: How Breaking with the Past Brought Peace to the Middle East"Topic: Israel-Hamas peace dealSee omnystudio.com/listener for privacy information.

Gov. Mike DeWine took executive action this week to temporarily ban the sale of "intoxicating hemp" products in the state. DeWine said the products represent a consumer product emergency. The order bans the sale of unregulated products that contain THC derived from hemp including candies and drinks. THC is the psychoactive compound found in the cannabis family of plants. DeWine's executive order is for 90 days. We will begin the “Sound of Ideas Reporters Roundtable” with the governor's executive action. The Ohio House this week passed -- with some support from Democrats -- two bills that proponents say will give property owners some tax relief. The two bills, which the Senate now takes up, make changes to how property taxes are determined and how schools and other local entities collect the money raised from levies. Eleven protesters have paid nearly $400,000 in restitution in a pretrial diversion program that, if all stipulations are met, will null charges they incurred while protesting the war in Gaza at Case Western Reserve University last year. The protesters, ages 20 to 25, splashed red paint on buildings and sidewalks. They were charged with breaking and entering, possessing criminal tools and vandalism. They spoke publicly last weekend, saying the university is making an example of them in order to quash pro-Palestinian protests. Early voting is underway for the November election. And in addition to levies and mayoral an council races, there is a robustly contested battle for four open seats on the Akron Board of Education. Eight candidates meet this week for a debate sponsored by the Akron Press Club in partnership with Ideastream Public Media, the Akron Beacon Journal and Signal Akron. Our Anna Huntsman was one of the journalists posing questions to the candidates. People are packing independent music venues. That's a good thing. But the venues aren't turning a profit. That's troubling. So says a new report from the National Independent Venue Association on the impact of small music clubs on the state's economy, which estimates the more than 300 clubs made $3 billion last year. Students, alumni and supporters of student-run WCSB college radio at Cleveland State University held a protest this week after the university announced an agreement with Ideastream Public Media to switch to an all-Jazz format programmed by Ideastream.

We continue to bring you the latest on the government shutdown and whether the two sides are any closer to working together. Justin Buchler, Associate Professor of Political Science at Case Western Reserve University, joins us.

Read the full transcript here. What does it mean to treat facts as drafts rather than monuments? If truth is something we approach, how do we act while it's still provisional? When definitions shift, what really changes? How do better instruments quietly rewrite the world we think we know? Are we mostly refining truths or replacing them? When do scientific metaphors clarify and when do they mislead? What public stories make self-correction legible and trusted? What features make science self-correct rather than self-congratulatory? How should we reward replication, repair, and tool-building? Do we need more generalists - or better bridges between tribes? How does measurement expand the very questions we can ask? Is progress a goal-seeking march or a search for interesting stepping stones? Should we teach computing as a liberal art to widen its aims? Will AI turn software into a home-cooked meal for everyone? How do we design tools that increase wonder, not just efficiency? Samuel Arbesman is Scientist in Residence at Lux Capital. He is also an xLab senior fellow at Case Western Reserve University's Weatherhead School of Management and a research fellow at the Long Now Foundation. His writing has appeared in the New York Times, the Wall Street Journal, and The Atlantic, and he was previously a contributing writer for Wired. He is the author of the new book The Magic of Code, and his previous books are Overcomplicated: Technology at the Limits of Comprehension and The Half-Life of Facts: Why Everything We Know Has an Expiration Date. He holds a PhD in computational biology from Cornell University and lives in Cleveland with his family. Links: Sam's Recent Titles: The Half-Life of Facts and The Magic of Code Staff Spencer Greenberg — Host + Director Ryan Kessler — Producer + Technical Lead Uri Bram — Factotum WeAmplify — Transcriptionists Igor Scaldini — Marketing Consultant Music Broke for Free Josh Woodward Lee Rosevere Quiet Music for Tiny Robots wowamusic zapsplat.com Affiliates Clearer Thinking GuidedTrack Mind Ease Positly UpLift [Read more]

Send us a textThis week on Here's What We Know, we welcome Dr. Dan Docherty, Chief Coaching Officer of Braintrust and a leadership development expert, for an inspiring conversation about the heart of human connection. We'll explore how communication, neuroscience, and mentorship shape who we become as leaders, parents, and friends.From the story of a music teacher who changed Dan's life to the Six P's framework that can transform any relationship, this episode is packed with insights on purpose, empathy, and growth. It's a conversation that reminds us all to reach out, say thank you, and keep learning from the people who believed in us first.In This Episode:Why great communication is the greatest gift we can giveDiscover how personal setbacks can become powerful springboards for growthHow applied neuroscience helps us connect more deeplyLearn practical frameworks (like the Six P's) that transform everyday interactions into moments of real impactThe difference between wisdom and knowledgeSimple steps to discover your personal “why”A touching reunion story decades in the makingThis episode is sponsored by:Dignity MemorialBio:Dan Docherty, PhD, Chief Coaching Officer of Braintrust, has found a true passion for creating world-class communicators that make a positive difference. His 25 years of experience in leading various sales, marketing, MSL, and operational pharmaceutical teams, led him to a PhD degree in Management at Case Western Reserve University where his research was focused on the neuroscience of coaching, engagement, and performance in the leader-team member relationship. All of this led to a commitment to the science behind brilliant and effective leadership, and ultimately, the co-creation of NeuroCoaching®.Dr. Dan has coached thousands of leaders in management positions around the world, all while continuing to pour into the lives and futures of students in his own backyard at Miami University in Oxford, OH. Dan teaches courses in management, leadership coaching, and entrepreneurship within undergraduate, MBA, and executive education at the Farmer School of Business. From the world-renowned mentors of his doctorate program to the wisdom shared by his small-town high school music teacher, Dan knows firsthand just how formative good leadership can be to the individual, thus leading to stronger organizations, communities, and families.Website: https://dandocherty.com/LinkedIn: https://www.linkedin.com/in/dan-docherty/Instagram: https://www.instagram.com/drdandocherty/Connect with Gary: Gary's Website Follow Gary on Instagram Gary's Tiktok Gary's Facebook Watch the episodes on YouTube Advertise on the Podcast Thank you for listening. Let us know what you think about this episode. Leave us a review!

Ever wonder why you still feel hungry after drinking a sugary soda? It turns out fructose doesn't trigger the same fullness signals in your brain that other sugars do. In this episode, I break down the science of fructose and how it affects your body differently than the natural sugars found in whole fruits. We explore how excess fructose from sodas, processed foods, and fruit juices can lead to fat buildup in your liver, raise your triglyceride levels, and increase your risk for metabolic dysfunction associated with liver disease. I also discuss how fructose impacts your heart health by causing inflammation and stiffness in your blood vessels, which can raise blood pressure. Plus, we talk about the connection between high uric acid levels from fructose and kidney damage over time. Tune in to learn practical steps you can take this week to reduce added sugars without feeling deprived, including simple swaps that protect your liver, heart, and kidneys.   Episode Highlights: The difference between natural fructose in whole fruits versus processed fructose  How the liver processes fructose  The impact of fructose on weight gain and hunger signals Cardiovascular effects of excess fructose The connection between fructose, uric acid levels, and kidney health Practical strategies to reduce fructose intake   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

#536: Richard Boyatzis is a distinguished university professor at Case Western Reserve University and one of the world's leading experts on intentional change and emotional intelligence. With degrees from MIT and Harvard, he has spent nearly six decades researching how people and organizations can create lasting, positive transformation. Richard is the author and co-author of ten books, including the international bestseller Primal Leadership, Helping People Change, and his newest release The Science of Change. His work blends neuroscience, psychology, and organizational behavior to uncover how vision, renewal, and resonant relationships drive real growth - making him a go-to voice for anyone looking to reimagine their career, leadership, or life.

Welcome to Mysteries to Die For.I am TG Wolff and I'm here with Jack, my piano player and producer. This is a podcast where we combine storytelling with original music to put you in the heart of a mystery. All stories are structured to challenge you to beat the detective to the solution. Jack and I perform these live, front to back, no breaks, no fakes, no retakes.A special announcement…our social media is alive and kicking. Check out Instagram @mysteriestodiefor (all spelled out) and on Facebook @m2d4podcast for the pulse on the shows happenings. And explore our website, M2D4Podcast.com for all our episodes and authors.The rules for law and order create the boundaries for civil co-existence and, ideally, the backdrops for individuals, families, and companies to grow and thrive. Breaking these rules puts civil order at risk. And while murder is the Big Daddy of crimes, codified ordinances across municipal divisions, counties, states, and countries show the nearly endless ways there are to create mayhem. This season, we put our detective skills to the test. This is Season 8, Anything but Murder. This is Episode 19, Body Snatching is the featured crime. This is Have You Seen This Body? by TG WolffCome back in 2 weeks for the conclusion of Have You Seen This Body?About TG WolffLike you, I'm not one thing. I'm a writer, an engineer, a wife, and a mother. What is first on the list depends on the day. Beyond the title I claim, I'm a person who loves learning and thoroughly enjoys a good puzzle, is creative and gets bored easily. I hold a BS in Civil Engineering from Case Western Reserve University and an MS in Civil Engineering from Cleveland State University, which gives me absolutely no background in writing, but I do it anyway. Writing mysteries and engineering isn't as different as you'd think. Both require using logic and process to get from a starting problem to a solution.Find me at www.tgwolff.com

Roughly 1 in 10 Americans take antidepressants. The most common type is SSRIs, or  selective serotonin re-uptake inhibitors, like Prozac, Lexapro, and Zoloft. But what happens when you stop taking them? Studies don't point to a single conclusion, and there's ongoing debate among physicians and patients about the severity and significance of SSRI withdrawal symptoms. The discourse reached a fever pitch when Health Secretary Robert F. Kennedy Jr. compared SSRI withdrawal to heroin withdrawal in January.Host Flora Lichtman digs into the data on SSRI withdrawal with psychiatrists Awais Aftab and Mark Horowitz.Guests: Dr. Awais Aftab is a clinical associate professor of psychiatry at Case Western Reserve University.Dr. Mark Horowitz is a clinical research fellow in the UK's National Health Service and  scientific co-founder of Outro Health.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Mike Swiger is the founder and Executive Director of True Freedom Ministries,  Ohio's largest prison ministry. While attending Case Western Reserve University, Mike was convicted as an accomplice in a crime committed by his older brother and served 17 years for involuntary manslaughter. During his incarceration, he earned two associate degrees and later graduated summa cum laude from Ohio University with a Bachelor of Business Administration.  Mike also holds a degree in theology from Reformed Theological Seminary.  Plus, he's an award-winning author of the Innocents Series - inspirational, suspense-filled legal thrillers.  Tune in to see how Jesus has changed his life! Mike's Books Here True Freedom Ministries Website True Freedom Ministries Instagram True Freedom Ministries Facebook Page Youtube For True Freedom MInistries Here ______________________________ Follow me on my Instagram or Facebook Podcast Facebook page here Check out KristiCapel.com Email: Kristicapelpodcast@gmail.com  

Dr. Paul Tesar is the Director of the Institute for Glial Sciences and the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics at Case Western Reserve University. His lab uses PSCs to model neurological development and disease with a specific focus on oligodendrocytes and astrocytes. He talks about his work on oligodendrocyte maturation, advancing research into the commercial and clinical sectors, and mentoring the next generation of scientists.

Can body positivity and weight loss medications like Ozempic and WeGovy coexist. Or are they destined to clash? This question has sparked debates across social media and medical offices everywhere. In this episode, I will explore the history of the body positivity movement from its 1960's roots with the National Association to Advance Fat Acceptance to its social media explosion in the 2010's. I will discuss how the movement challenged diet culture and promoted self-love regardless of size. Then, I will also talk about today's weight loss medication revolution and the tension it creates. Some feel that taking these drugs contradicts body positivity principles, while others face judgement for choosing medical intervention. I will address the stigma from both sides, the challenge of redefining health, and how to separate personal choice from cultural pressure. Tune in to discover why these two movements don't have to be at war and how you can find a middle ground of honoring your own health journey without judgment.   Episode Highlights: The history and evolution of body positivity movement How society judges people based on size and the ongoing work needed. The rise of drugs like Zepbound and WeGovy and their health benefits The tension between these two movements seeing it as incompatible to each other's principles. How to embrace both self-acceptance and medical tools for health.   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Michael Rectenwald discusses his newly founded Anti-Zionist America PAC (AZAPAC) which exists to end America's political, financial, and military entanglement with Israel. He explains what has gone wrong with Zionist influence, how its mask has come off under the Trump administration, the attack on civil liberties, the devastation of Gaza, and more. He also gives an update on where we're at with the globalist project for a technocratic world state. Watch on BitChute / Brighteon / Rumble / Substack / YouTube Geopolitics & Empire · Michael Rectenwald: Disentangling the Zionist Lobby Through AZAPAC #572 *Support Geopolitics & Empire! Become a Member https://geopoliticsandempire.substack.com Donate https://geopoliticsandempire.com/donations Consult https://geopoliticsandempire.com/consultation **Visit Our Affiliates & Sponsors! Above Phone https://abovephone.com/?above=geopolitics easyDNS (15% off with GEOPOLITICS) https://easydns.com Escape The Technocracy (15% off with GEOPOLITICS) https://escapethetechnocracy.com/geopolitics Expat Money Summit 2025 (20% off VIP with EMPIRE) https://2025.expatmoneysummit.com PassVult https://passvult.com Sociatates Civis https://societates-civis.com StartMail https://www.startmail.com/partner/?ref=ngu4nzr Wise Wolf Gold https://www.wolfpack.gold/?ref=geopolitics Websites Michael Rectenwald https://www.michaelrectenwald.com AZAPAC https://www.aza-pac.com Substack https://mrectenwald.substack.com X https://x.com/RecTheRegime About Michael Rectenwald Dr. Michael Rectenwald is the author of twelve books, including The Great Reset and the Struggle for Liberty: Unraveling the Global Agenda (Jan. 2023), Thought Criminal (Dec. 2020); Beyond Woke (May 2020); Google Archipelago: The Digital Gulag and the Simulation of Freedom (Sept. 2019); Springtime for Snowflakes: “Social Justice” and Its Postmodern Parentage (an academic's memoir, 2018); Nineteenth-Century British Secularism: Science, Religion and Literature (2016); Academic Writing, Real World Topics (2015, Concise Edition 2016); Global Secularisms in a Post-Secular Age (2015); Breach (Collected Poems, 2013); The Thief and Other Stories (2013); and The Eros of the Baby-Boom Eras (1991). (See the Books page.) Michael was a distinguished fellow at Hillsdale College and a Professor of Liberal Studies and Global Liberal Studies at NYU. He also taught at Duke University, North Carolina Central University, Carnegie Mellon University, and Case Western Reserve University. His scholarly and academic essays have appeared in The Quarterly Journal of Austrian Economics, Academic Questions, Endeavour, The British Journal for the History of Science, College Composition and Communication, International Philosophical Quarterly, the De Gruyter anthologies Organized Secularism in the United States and Global Secularisms in a Post-Secular Age, and the Cambridge University Press anthology George Eliot in Context, among others (see the Academic Scholarship page). He holds a Ph.D. in Literary and Cultural Studies from Carnegie Mellon University, a Master's in English Literature from Case Western Reserve University, and a B.A. in English Literature from the University of Pittsburgh. (See his C.V. for details.) Michael's writing for general audiences has appeared on The Mises Institute Wire, Newsweek, The Epoch Times, RT.com, Campus Reform, The New English Review, The International Business Times, The American Conservative, Quillette, The Washington Post, Pittsburgh Post-Gazette, CLG News, LotusEaters.com, Chronicles, and others. (See the Essays and Presentations page.) Michael has appeared on major network political talk shows (Tucker Carlson Tonight, Tucker Carlson Originals, Fox & Friends, Fox & Friends First, Varney & Company, The Ingraham Angle, Unfiltered with Dan Bongino, The Glenn Beck Show), on syndicated radio shows (Coast to Coast AM, Glenn Beck, The Larry Elder Show, and many others),

In Today's Episode... In this conversation, Ed Vargo shares his unique journey as a male financial advisor working with women, influenced by his mother's struggles with financial literacy during her divorce. He discusses the significant differences in how men and women engage with money, emphasizing the need for women to take an active role in financial discussions within relationships. Ed advocates for bridging the financial literacy gap for women, particularly younger women, to empower them in their financial decisions and align their spending with their values. In this conversation, Ed Vargo and Jordan Pendleton explore the complexities of financial conversations within relationships, emphasizing the importance of aligning day-to-day spending with long-term financial goals. They discuss the different perspectives men and women often have regarding finances, particularly in the context of marriage and divorce. The discussion highlights the necessity of regular communication about financial goals, the challenges of navigating these conversations, and the potential benefits of seeking professional financial advice. Connect with Ed Website  Instagram Facebook Resources & Free Guides  “9 Money Myths You Must Bust (Before they Hurt the Next Generation)” “The Empowered Exit: 12 Steps to Safeguard your Financial and Emotional Well-Being”  Full Program “Divorce Navigator” : A comprehensive program guiding women through the legal, emotional, and financial aspects of divorce.  About Ed Vargo Ed Vargo, CFP®, CLU®, ChFC®, AIF®, CDFA®, founder of Burning River Advisory Group, grew up in inner-city Cleveland. His mother, a first-generation immigrant, struggled financially and was stuck in an unhealthy relationship. Her challenges left a lasting imprint on Ed and his values as a husband, father, and advisor. Ed's father, a steelworker and single dad, raised four children in Cleveland's Slavic Village. Ed attended Case Western Reserve University, earning a BS in Management and meeting his college sweetheart, Wendy. Now the proud parents of five charismatic daughters, Ed and Wendy are deeply committed to women's empowerment. Ed believes financial strength is essential to a woman's health, safety, and opportunity. His commitment to helping women achieve financial independence runs through the heart of Burning River, where he provides customized financial solutions with a compassionate and caring hand.   Don't forget about this amazing free offer from Jordan. She put a lot of time and effort into this project to be able to offer it to you, absolutely free! Take advantage now while you can! eBook: Couples Guide to Getting on the Same Page About Money   Reminder: Subscribe, Rate & Review this podcast!   Whatever platform you are listening on, make sure to follow or subscribe & sign up for notifications for when weekly episodes drop every week! And if you feel called, please leave a rating and review. This helps us to reach more people!  JordanPendleton.com

The university's Inamori International Center for Ethics and Excellence will award Oscar Chacón with the 2025 Inamori Ethics Prize for his work in human rights and immigration justice.

Tenth grade is a pivotal year for college preparation, and this episode is your comprehensive guide! Join host Tasha (formerly at Boston University and USC) as she sits down with expert IvyWise counselors Phuong (formerly at Babson College) and Rod (formerly at Case Western Reserve University) to break down exactly what sophomores need to do to build a strong foundation for college admissions.

We're getting closer to a government shutdown, and Congress still hasn't acted. We get the latest with Justin Buchler, Associate Professor of Political Science at Case Western Reserve University

In this episode of the Charity Charged show, Dr. Jacklyn Chisholm, president and CEO of Step Forward, discusses the organization's mission to empower low-income families towards self-sustainability. She shares insights on transforming organizational culture, the importance of trust in leadership, and the challenges of navigating funding in the nonprofit sector.Dr. Chisholm emphasizes the need for nonprofits to balance business acumen with their charitable missions, advocating for a sustainable future for organizations like Step Forward.About Dr. Jacklyn ChisholmA lifelong learner, Dr. Chisholm is a Harvard Business School alumna with additional executive education credentials from the Harvard Kennedy School, Wharton School, and Cornell University. She holds a B.A. in Medical Anthropology, M.A. in Psychological Anthropology, and a Ph.D. in Psychological Anthropology with a focus in Educational Anthropology from Case Western Reserve University.Dr. Chisholm has broken barriers throughout her career, including as the first Vice President of Planning and External Affairs at the Rock and Roll Hall of Fame and Museum, where she led the $13 million construction of its Library and Archives. At Case Western Reserve University, she was the first to hold multiple pioneering roles, including Associate Vice President for Community Partnerships and Director of Community Relations.Her work has earned widespread recognition, including the Crain's Cleveland Business Notable Leader in Philanthropy, Smart Business Progressive Woman Award, YWCA Woman of Achievement, and the Council for Opportunity in Education National TRIO Achiever Award, among many others. A proud Leadership Cleveland alumna, Dr. Chisholm continues to be a trailblazer in education, advocacy, and transformational leadership.About Charity Charge:Charity Charge is a financial technology company serving the nonprofit sector. From the Charity Charge Nonprofit Credit Card to bookkeeping, gift card disbursements, and state compliance, we help mission-driven organizations streamline operations and stay financially strong. Learn more at charitycharge.com.

A new study shows weight loss drugs like Wegovy and Zepbound don't just help with losing weight they may also protect the heart and save lives. In this episode, we look at a new study that followed over 90,000 people with obesity, type 2 diabetes, and heart failure. The results show that drugs like Wegovy and Zepbound don't just help with weight loss, they can cut the risk of death or hospitalization for heart failure nearly in half. We'll talk about why that matters, how these medications actually work in the body, and what you should know about side effects and access. Most importantly, we'll explore why this research could change how we think about treating obesity not just as a matter of weight, but as a way to save lives. Tune in to the full episode to hear how these weight loss drugs could also protect your heart.   Episode Highlights: The new JAMA study on Wegovy and Zepbound and their impact on heart health. How GLP-1 medications work in the body to lower risk. Why this matters for people with obesity, diabetes, and heart disease. Side effects, diet, and exercise considerations when using these drugs. Challenges with access and cost of these medications.   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Welcome to the 6th episode of our BTK/ASGBI series!  During this series, BTK fellow Agnes Premkumar and ASGBI hosts Jared Wohlgemut and Gita Lingam will compare and contrast various aspects of surgery between the United States and the United Kingdom, debating who does what better.  In this episode, we delve into surgical training, current challenges, and hopes for the future of surgical training in the US and the UK. We will be discussing the advent of the EPA curriculum in the US, the current challenge of obtaining a speciality position in the UK, and tips for making the resident to attending/junior faculty transition smoothly. Dr. Jeremy Lipman represents the US while Dr. Phil Pearce represents the UK in this thought-provoking conversation. Dr. Lipman is a colorectal surgeon at the Cleveland Clinic and the director of graduate medical education for all training programs at the Cleveland Clinic. Additionally, he is an Associate Dean for Graduate Medical Education and Professor of Surgery at Case Western Reserve University. He is passionate about surgical training and holds the James E. Sampliner Endowed Chair in Surgical Education.  Dr. Phil Pearce is a consultant in emergency general surgery in Oxford with interests in trauma, complex biliary disease, and most importantly a passion for training. Take a listen and let us know what you think- who does surgical education and training better?  References: Speciality training position in the NHS https://www.ft.com/content/e4b364c3-6a20-42ee-a9a5-ab9eea441c87?utm_source=chatgpt.com https://www.theguardian.com/society/2025/jul/02/nhs-in-england-told-to-slash-recruitment-of-overseas-trained-medics?utm_source=chatgpt.com Surgery job market in the US https://surgpli.com/the-state-of-surgery-as-a-career-in-2025/ EPA curriculum https://www.aamc.org/about-us/mission-areas/medical-education/cbme/core-epas Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

I'm excited to welcome back Jennie Young to the podcast. Jennie is here to talk about dating after divorce and how to protect yourself from getting tangled in the patterns you worked so hard to get yourself out of. She's the creator of the Burned Haystack Dating Method — a sharp and fiercely feminist approach to spotting danger early in the dating process, and the author of the upcoming book Burn the Haystack In our conversation, Jennie and I dig into the realities of dating after divorce: from spotting danger in seemingly “safe” profiles to challenging the patriarchal scripts that keep women waiting to be chosen. Plus, we talk about shifting into the seat of choice, what it looks like to feel genuinely comfortable being single, and how these changes ripple out into raising kids with healthier expectations. ✨ Podcast episodes are available in two formats - audio and video! If you'd like to watch the video version of this episode, you can find it here. What you'll hear about in this episode: Jennie shares her origin story and the ah-ha moment that led to creating The Burned Haystack Dating Method (2:31) The feminist philosophy behind Burned Haystack and how it flips the traditional “pick me” script (5:33) Why green flags can actually be red flags in disguise: from love bombing to performative sensitivity (15:25) The importance of being comfortable (and even happy) being single before re-entering dating (32:44) What the “extinction burst” in the toxic manosphere means, and why starving it of attention is essential (35:09) How to shift the messaging for our kids so they grow up with healthier expectations and values (42:39) Learn more about Jennie Young: Jennie Young is the creator of Burned Haystack Dating Method, a dating method grounded in applied rhetoric and feminist praxis. It is designed to combat many of the challenges of dating in a market that is too frequently mediated by misogynistic and patriarchal structures. She holds a Ph.D. in rhetoric and discourse studies from Case Western Reserve University and a satire writing certificate from Second City Chicago. Her work has been published in McSweeney's, Ms. Magazine, HuffPost, and others and covered by major media outlets such as The New York Times, Newsweek, RollingStone, and others. Resources & Links: ALL NEW: The Divorce Survival Guide Podcast Episodes are Now Available on YouTube! Focused Strategy Sessions with Kate The Divorce Survival Guide Resource BundlePhoenix Rising: A Divorce Empowerment CollectiveKate on InstagramKate on FacebookKate's Substack Newsletter: Divorce Coaching Dispatch Jennie's book Burn the HaystackJennie's Substack, Burned HaystackJennie's website Jennie's Facebook Group Jennie on Instagram Episode 317: Burned Haystack Dating Method with Jennie Young Episode 325: They Helped Me Find Love—Now They're Interviewing Me About It! With Alyssa Dineen and Jennie Young =================== DISCLAIMER:  THE COMMENTARY AND OPINIONS AVAILABLE ON THIS PODCAST ARE FOR INFORMATIONAL AND ENTERTAINMENT PURPOSES ONLY AND NOT FOR THE PURPOSE OF PROVIDING LEGAL OR PSYCHOLOGICAL ADVICE.  YOU SHOULD CONTACT AN ATTORNEY, COACH, OR THERAPIST IN YOUR STATE TO OBTAIN ADVICE WITH RESPECT TO ANY PARTICULAR ISSUE OR PROBLEM. =================== Episode link: https://kateanthony.com/podcast/episode-336-breaking-patterns-choosing-power-dating-after-divorce-with-jennie-young/  

In this episode, Dr. Goutham Rao, Chair of Family Medicine and Community Health at University Hospitals of Cleveland and Case Western Reserve University, shares insights on the global challenges of recruiting primary care physicians. He discusses strategies for making the work more engaging, the role of innovation and AI, and how to inspire future physicians through meaningful connections with patients.

Stanley Bazarek, MD, and Jennifer Sweet, MD, discuss the latest advances in neuromodulation, peripheral nerve surgery, and neuroengineering, highlighting the critical role of multidisciplinary collaboration between UH, Case Western Reserve University, and national research partners in translating these innovations from the lab to patient care. Learn more about Stanley Bazarek, MD Learn more about Jennifer Sweet, MD Learn more about the University Hospitals Research & Education Institute Follow Us on Social:      

Jason Toth was named senior associate vice president for administration for the University of Toledo in January 2019. He oversees the University's Facilities & Construction and Supply Chain offices.In his role, Toth leads the planning, directing, and monitoring of facilities operations and maintenance for the physical plant of the University. He is also responsible for the coordination and management of capital construction projects, aligning them with the University's Strategic and Campus Master Plans. Additionally, Toth leads the supply chain management division which handles University procurement, Shipping/Receiving/Mail Services/Surplus Property, along with the University of Toledo Medical Center's central distribution and linen services areas.Toth joined the University in 2011 as the Director of Facilities/Civil Engineer. He oversaw the re-engineering of the department's Construction Project Management Team. He applied his expertise to streamline processes and create efficiencies resulting in increased customer satisfaction and a reduction to the University's deferred maintenance liability.In 2012 Toth was promoted to University Chief Engineer, in 2013 to Associate Vice President, and in 2019 to Senior Associate Vice President. Under his leadership the departments for which he provides oversight strive to provide exceptional environments, deliver top end service, and promote the University's mission to improve the human condition.Prior to joining UToledo, Toth spent 13+ in the construction management field working for Bostleman Corporation.Toth received his Bachelor of Science in Civil Engineering from Case Western Reserve University. He is a LEED accredited professional and attended the Harvard Graduate School of Education, Institute for Educational Management.Jason has been happily married to his wife Janell for 27+ years.  They have 5 children – Addison, Broc, Carson, Delaney, and Eli (ABCDE) and two adorable grand children (Julia – 5 and Sadie – 2).  In his free time he enjoys walking, hiking, cycling and has been coaching youth sports for nearly 30yrs.

Send us a textEver wonder how your earliest experiences shape your entire worldview? Steve Scheidt knows firsthand. After spending his first five years in Nairobi, Kenya, his return to the United States came with a startling question at the Chicago Zoo: "Why are all the animals behind bars?" Having only known wildlife in their natural habitat, Steve's perspective was forever changed by these formative experiences.From those unique beginnings, Steve shares his journey through athletics, education, and family life that led him to his current role at Case Western Reserve University's Weatherhead School of Management. His story weaves through college rowing practices at dawn, the warmth of Italian family gatherings centered around food, and the unexpected path from journalism student to education professional.The conversation takes a profound turn when Steve reflects on parenting and the accelerating nature of time as we age. "You don't want to be the person saying 'I wish I would have done that,'" he advises, emphasizing the critical importance of being fully present in each moment with loved ones. His observations about how technology affects today's students compared to previous generations offers thought-provoking insights about connection in the digital age.Throughout the episode, Steve's warmth and wisdom shine through, particularly when discussing the value of meaningful relationships and genuine human connection. His final message about kindness and inclusion serves as a powerful reminder that how we treat others ultimately defines our legacy as we measure our lives not in months, but in decades.Join us for this heartfelt conversation about worldview, presence, and the moments that truly matter. Whether you're navigating career choices, parenting challenges, or simply seeking to live more intentionally, Steve's journey offers valuable perspective that will resonate long after the episode ends.Subscribe for exclusive content: https://www.buzzsprout.com/1530455/support Buzzsprout - Let's get your podcast launched!Start for FREETactical BrotherhoodThe Tactical Brotherhood is a movement to support America.Dubby EnergyFROM GAMERS TO GYM JUNKIES TO ENTREPRENEURS, OUR PRODUCT IS FOR ANYONE WHO WANTS TO BE BETTER.ShankitgolfOur goal here at Shankitgolf is for everyone to have a great time on and off the golf courseSweet Hands SportsElevate your game with Sweet Hands Sports! Our sports gloves are designed for champions,Buddy's Beard CareBuddy's Beard Care provides premium men's grooming products at an affordable price.Deemed FitBe a part of our movement to instill confidence motivation and a willingness to keep pushing forwardDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showFollow us on all social mediaX: @mikebonocomedyInstagram: @mikebonocomedy@tiktok: @mikebono_comedianFacebook: @mikebonocomedy

In this episode, Dr. Goutham Rao, Chair of Family Medicine and Community Health at University Hospitals of Cleveland and Case Western Reserve University, shares insights on the global challenges of recruiting primary care physicians. He discusses strategies for making the work more engaging, the role of innovation and AI, and how to inspire future physicians through meaningful connections with patients.

Have you heard about people buying weight loss medications from unregulated sources online? The rise of black market weight loss drugs is putting lives at risk. In this episode, I discuss the concerning trend of people purchasing Retatrutide—a medication still in clinical trials—through illegal channels. Known as the "Godzilla Jab" for its potential power, early studies suggest this drug could help people lose up to 24% of their body weight. I explain what Retatrutide is and how it compares to FDA-approved medications like Ozempic, Wegovy, Zepbound, and Mounjaro. We explore why people take dangerous risks with black market drugs, from social media hype to cost concerns and access issues. Most importantly, I share the serious health and legal risks of buying unregulated medications and provide clear guidelines for safely accessing weight loss treatments through licensed providers. Tune in to learn how to protect yourself and make informed decisions about weight loss medications the safe way.   Episode Highlights: What is Retatrutide The dangers of purchasing unregulated medications online Factors driving people to illegal sources Legal risks of buying unapproved drugs and potential health complications from unregulated substances Safe Medication Practices Understanding that medication works best when combined with healthy eating, physical activity, adequate rest, and emotional support   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

What if the conventional narrative of the 1960s civil rights era, by its very nature, limits the success, legal achievements, and persistence of Black Americans for generations? In Before the Movement: The Hidden History of Black Civil Rights, author Dylan C. Penningroth maintains that the fight for civil rights didn't begin with famous marches and courtroom cases of the 1960s. Instead, his research stretches from the last decades of slavery to the 1970s, and challenges nearly every aspect of our traditional understanding of civil rights history as we know it.rnrnDrawing on long-forgotten sources found in the basements of county courthouses across the nation, Penningroth centers the everyday lives of Black Americans and sheds light on their centuries-long tradition of legal knowledge to assert their rights, protect their families, and shape their communities.rnrnDylan C. Penningroth is a professor of law and Morrison Professor of history at the University of California, Berkeley. He specializes in African American history and legal history and is a MacArthur Fellow. Before the Movement won eleven book prizes and was shortlisted for four more. He is also the author of the award-winning book, The Claims of Kinfolk: African American Property and Community in the Nineteenth-Century South.

Send us a textEver wondered who orchestrates the complex symphony of college athletics? In this riveting conversation with TJ Shelton, Director of Athletics and Chair of the Physical Education Department at Case Western Reserve University, we pull back the curtain on collegiate sports administration and discover the invisible architecture that supports student-athletes.TJ brings a wealth of experience to our discussion, having spent 15 years at Ohio State University before taking the helm at Case Western in 2022. What makes his perspective particularly valuable is his experience across both Division I and Division III athletics, highlighting the unique aspects of each environment. At Case Western, coaches don't just coach—they teach as faculty members, creating a seamless integration between academics and athletics that defines the Division III experience.The conversation takes us through the daily challenges of athletic administration, from coordinating travel for multiple teams to ensuring proper medical support for student-athletes. "You're kind of like officials," TJ explains. "If you're part of the game, then something went wrong." This insight perfectly captures the essence of effective athletic leadership—creating environments where athletes can focus entirely on performance while administrators handle everything else. We explore how hosting NCAA championships requires meticulous planning, from managing team buses to coordinating facilities, all with the goal of allowing student-athletes to "sleep in their own beds" during important competitions.Beyond the logistics, TJ shares heartfelt reflections on how sports build character and prepare young people for life's challenges. As both an administrator and a father, he's witnessed firsthand how athletics instill accountability, teamwork, and work ethic that translate directly to success in academics and careers. For listeners considering colleges for themselves or their children, TJ offers compelliSubscribe for exclusive content: https://www.buzzsprout.com/1530455/support Buzzsprout - Let's get your podcast launched!Start for FREETactical BrotherhoodThe Tactical Brotherhood is a movement to support America.Dubby EnergyFROM GAMERS TO GYM JUNKIES TO ENTREPRENEURS, OUR PRODUCT IS FOR ANYONE WHO WANTS TO BE BETTER.ShankitgolfOur goal here at Shankitgolf is for everyone to have a great time on and off the golf courseSweet Hands SportsElevate your game with Sweet Hands Sports! Our sports gloves are designed for champions,Buddy's Beard CareBuddy's Beard Care provides premium men's grooming products at an affordable price.Deemed FitBe a part of our movement to instill confidence motivation and a willingness to keep pushing forwardDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showFollow us on all social mediaX: @mikebonocomedyInstagram: @mikebonocomedy@tiktok: @mikebono_comedianFacebook: @mikebonocomedy

In episode 139, we chat with Melanie Falls, a member of the National Board of Directors for the Human Rights Campaign (HRC), about the amazing work the organization has done and continues to do.Melanie has been involved in advocacy for the LGBTQ+ community for over thirty-five years. She has worked on the lecture circuit throughout NE Ohio educating about the LGBTQ+ community. She has presented at NEOUCOM, University Hospital's Medical School, Social Work and Counseling Conferences to name a few.She is a founding member of Equality Ohio and served as Board Chair in 2007-2008. A general member of HRC for over ten years, she began active volunteering as a member of the Cleveland Gala Committee moving on to be the Gala Co-Chair for two years. As a member of the Cleveland Steering Committee, she held numerous positions including Steering Committee Co-Chair, Federal Club Tri-Chair and Diversity Equity and Inclusion liaison to the national office.She has been an HRC Federal Club speaker for Cleveland, Columbus and St. Louis. Melanie served as an HRC Governor from 2015 to 2017 and has been on the National Board of Directors since 2017. As a National Director, she has co-chaired the National Public Policy Committee and served on the Board Diversity Committee and Board Development Committee. Melanie is a Licensed Independent Social Worker. She has worked extensively throughout Northeast Ohio in mental health counseling, foster care and adoption. Her expertise is in Trauma Treatment, Women's Mental Health Issues, Marriage and Family therapy and LGBTQIA mental health and relationships concerns. Melanie retired in 2015 as the Executive Director of Applewood Centers, Inc. a child and family Mental health agency. Since retirement from Applewood Centers, Inc. she has been working as a private practitioner at Lifestance Health, a national mental health organization. She has been an adjunct professor and a program consultant at the Mandel School of Applied Social Sciences at Case Western Reserve University. Melanie has been legally married to her wife Tina for twenty-one years. They've been together for thirty years. Together they have raised Melanie's four biological children, two sons and two daughters and have eight grandchildren. Grandparenting is their favorite and cherished pastime. Don't ask them about their grandchildren unless you have a few hours to spare. Their intimate Sunday dinners often number 18.Resources: * Human Rights Campaign: HRC WebsiteConnect with USS:* Substack* Instagram* TikTokThis episode was edited by Kevin Tanner. Learn more about him and his services here:* Website* Instagram Get full access to United SHE Stands at www.unitedshestands.com/subscribe

A local professor from Case Western Reserve University is one of dozens of scientists who are pushing back against a Department of Energy report.

Check out my top picks for skin care here. Download the Free eBook 'Skincare Myths Busted' What do you do when the face in the mirror doesn't match how you feel inside? Welcome to the skin shift that happens in midlife — a direct result of hormonal changes, specifically the drop in estrogen that comes with perimenopause and menopause. And while it's common, it's not talked about enough. Until now. In this episode, I sit down with Dr. Pooja Rambhia, a board-certified dermatologist who's leading the conversation around what's been coined the “menopause makeover.” This is about understanding what's happening in your skin and body during menopause, and how to support both with science, compassion, and the right strategies. From collagen loss to skin laxity to the real reason your products aren't working anymore, we cover it all. We also talk about realistic solutions, from injectables and resurfacing lasers to hormone therapy and everyday skincare that actually supports your skin at this stage of life. This episode is not about “fixing” your face. It's about finally getting answers to the questions so many women are asking and doing so with a sense of clarity. Key Takeaways: Skin loses up to 30% of its collagen in the first five years after menopause. Estrogen is important for your skin's hydration, elasticity, thickness, and glow. It's normal to experience acne, dryness, sagging, and texture changes but that doesn't mean you have to just accept it. Bio-stimulatory injectables, topical actives, laser treatments, and even hormone replacement therapy can all play a role when used wisely and intentionally. Aging is not a decline. It's a transition that deserves support, not shame. Pooja H. Rambhia, MD, is a board-certified dermatologist with specialized fellowship training in cosmetic dermatology and laser surgery. She practices at UnionDerm in New York City and Greenwich, CT, providing comprehensive dermatologic care and specializing in laser treatments, injectables, and facial and body contouring for all skin types. Dr. Rambhia completed her medical training at Case Western Reserve University and dermatology residency at Zucker School of Medicine/Northwell Health, where she served as Chief Resident. She then completed the prestigious American Society for Dermatologic Surgery Fellowship at UnionDerm with Dr. Anne Chapas. Committed to advancing the field of dermatology, Dr. Rambhia has published numerous peer-reviewed articles in leading journals and presented her research at major national conferences including the American Academy of Dermatology and the American Society for Dermatologic Surgery. Her expertise has been featured in major media outlets including Vogue, Allure, Marie Claire, InStyle, Elle and The New York Times. Dr. Rambhia is dedicated to delivering personalized, natural-looking results while combining artistry with the latest scientific innovations in aesthetic dermatology. Follow Dr. Rambhia here: https://www.instagram.com/drpoojarambhia/?hl=en https://www.instagram.com/unionderm/?hl=en https://www.unionderm.com/ Download my Free Guide 'In My Perimenopause Era'

On today's episode we're focusing on wearable technology for athlete performance, recovery and injury prevention with Dr. Jacob Calcei, an orthopedic surgeon at University Hospitals in Cleveland and team physician for the Cleveland Browns. We'll start off our discussion today with an article titled “Wearable Performance Devices in Sports Medicine” from the January 2016 issue of Sports Health. The authors review the rapid rise of wearable sensor technologies in athletics, highlighting their ability to track real-time physiologic and movement data for optimizing performance and reducing injury risk. These tools can provide valuable insights into workloads, biomechanics, and fatigue, supporting tailored training programs and early injury prevention strategies. While wearable devices have shown promise, evidence for their effectiveness in professional sports remains limited, and further research is needed to validate accuracy, develop standardized training protocols, and address practical challenges such as reliability and usability.Then, from the January 2020 issue of Sports Heath, we review an article titled “Does Overexertion Correlate With Increased Injury? The Relationship Between Player Workload and Soft Tissue Injury in Professional American Football Players Using Wearable Technology.” This study investigates whether sudden increases in training load, as measured by wearable GPS and accelerometry technology, are associated with higher rates of soft tissue injury in professional American football players.  The authors analyzed two NFL seasons and found that injured players experienced significantly greater spikes in workload during the week of injury compared to the prior month. Specifically,  they found that those exceeding an acute-to-chronic workload ratio (ACR) of 1.6 being 1.5 times more likely to sustain an injury. The effect was particularly pronounced in the preseason, when workloads were higher and hamstring injuries were most common. The findings suggest that rapid workload increases predispose athletes to soft tissue injury, while consistent training loads may offer a protective effect. The authors conclude that monitoring player workload with wearable technology could help medical and training staff design safer, more individualized training regimens to reduce injury risk.We are joined today by Dr. Jacob Calcei, a board-certified orthopedic sports medicine physician and shoulder surgeon at University Hospitals and an assistant professor of Orthopedic Surgery at Case Western Reserve University School of Medicine. He is a team physician for the Cleveland Browns as well as several local high schools. Dr. Calcei has published extensively on a variety of sports medicine topics, has a particular interest in injury prevention and finding ways that we can make sports safer while optimizing athlete performance. So, we're very excited to have him join us today.

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Ivy Zelman is one of the most respected voices in American housing, co-founder of Zelman & Associates, and now Executive Vice President at Walker & Dunlop, which acquired her firm in 2021 as the leading institutional research, advisory, and investment banking firm dedicated exclusively to the U.S. housing industry.Over the last three decades, Ivy has built a reputation for bold, contrarian analysis—famously calling the top of the housing market in 2005 and the bottom in 2012—moments that cemented her as a rare analyst unafraid to speak truth to consensus. That conviction has earned her numerous accolades, including recognition in Barron's 100 Most Influential Women in U.S. Finance for four consecutive years and induction into the California Homebuilding Foundation's Hall of Fame.In our conversation, we trace Ivy's journey from falling into equity research to taking the entrepreneurial leap in 2007, founding Zelman & Associates amid the looming financial crisis. We explore her approach to research and analysis—blending proprietary surveys with a nationwide network of builders, brokers, and lenders—to consistently separate signal from noise.We reflect on her evolution as a leader and entrepreneur, the culture she has cultivated with a team that has stayed by her side for decades, her love of Cleveland, and what it means to pay it forward today through teaching and mentorship as an Adjunct Professor of Finance at Case Western Reserve University, her memoir Gimme Shelter, and much more.00:00:00 - Catalytic Moments in Finance00:08:25 - Recognizing Blind Spots in Research00:11:27 - The Entrepreneurial Inclination00:11:55 - Building Conviction and Confidence00:15:54 - Vision for Success00:17:21 - Detective Work in Research00:18:45 - Cultivating a Strong Network00:22:20 - The Importance of Asking the Right Questions00:25:13 - Reconciliation with Reality00:26:35 - Navigating Market Sentiment00:28:13 - The Evolution of Zellman Associates00:30:38 - Personal Growth as an Entrepreneur00:34:06 - Leadership and Team Development00:36:01 - Maintaining Intellectual Honesty Post-Acquisition00:37:39 - Understanding the Value of Research00:39:15 - Cleveland's Unique Perspective00:42:10 - Paying It Forward and Mentorship00:45:38 - Lessons for the Next Generation00:47:23 - Contrarian Views on Market Trends00:49:17 - Balancing Work and Family Life00:51:20 - Hidden Gem-----LINKS:https://www.linkedin.com/in/ivy-zelman-64304616b/https://www.zelmanassociates.com/https://www.amazon.com/Gimme-Shelter-Skills-Street-Trailblazer/dp/1737709929-----SPONSOR:Roundstone InsuranceRoundstone Insurance is proud to sponsor Lay of The Land. Founder and CEO, Michael Schroeder, has committed full-year support for the podcast, recognizing its alignment with the company's passion for entrepreneurship, innovation, and community leadership.Headquartered in Rocky River, Ohio, Roundstone was founded in 2005 with a vision to deliver better healthcare outcomes at a more affordable cost. To bring that vision to life, the company pioneered the group medical captive model — a self-funded health insurance solution that provides small and mid-sized businesses with greater control and significant savings.Over the past two decades, Roundstone has grown rapidly, creating nearly 200 jobs in Northeast Ohio. The company works closely with employers and benefits advisors to navigate the complexities of commercial health insurance and build custom plans that prioritize employee well-being over shareholder returns. By focusing on aligned incentives and better health outcomes, Roundstone is helping businesses save thousands in Per Employee Per Year healthcare costs.Roundstone Insurance — Built for entrepreneurs. Backed by innovation. Committed to Cleveland.-----Stay up to date by signing up for Lay of The Land's weekly newsletter — sign up here.Past guests include Justin Bibb (Mayor of Cleveland), Pat Conway (Great Lakes Brewing), Steve Potash (OverDrive), Umberto P. Fedeli (The Fedeli Group), Lila Mills (Signal Cleveland), Stewart Kohl (The Riverside Company), Mitch Kroll (Findaway — Acquired by Spotify), and over 200 other Cleveland Entrepreneurs.Connect with Jeffrey Stern on LinkedIn — https://www.linkedin.com/in/jeffreypstern/Follow Lay of The Land on X @podlayofthelandhttps://www.jeffreys.page/

Your liver could be silently struggling right now and the good news is, you can turn it around. In this episode, I dive deep into the topic of metabolic dysfunction-associated steatotic liver disease, also known as fatty liver disease. I explain what it is, why the medical community updated the name, and why it matters for long-term health. I highlight who is most at risk, including people with obesity, diabetes, high blood pressure, or high cholesterol and why the condition is often called a “silent disease” since many don't realize they have it. I also break down the potential dangers if it progresses, from inflammation to cirrhosis, and share the encouraging news that it's often reversible with lifestyle changes. My goal is to empower listeners to protect their liver and overall health with small, sustainable changes.  Take control of your health and tune in to this episode to learn how you can prevent, reverse, and protect your liver from fatty liver disease with simple, sustainable steps!   Episode Highlights: What MASLD is and why the name changed from NAFLD Why fatty liver disease is becoming more common and who's most at risk Signs, symptoms, and why it's often called a “silent disease” Potential complications, including inflammation, fibrosis, and cirrhosis How fatty liver is diagnosed through blood tests, imaging, or scans Lifestyle strategies to reverse or prevent progression  The role of managing diabetes, cholesterol, and blood pressure in protecting liver health FDA-approved medications such as Wegovy and others that may help in treatment Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

You can also watch the video version of this episode on dvm360.com Alice Jeromin, RPh, DACVD—Before earning her DVM degree from The Ohio State University, Jeromin graduated from the University of Toledo with a BS in Pharmacy and practiced as a hospital pharmacist. She completed her veterinary dermatology residency with Patrick Breen and dermatopathology training at Procter & Gamble, Miami Valley Labs, as well as a fellowship in human dermatology at Metro Health Medical Center, Cleveland, Ohio with Bryan Davis. Jeromin is currently an adjunct professor at Case Western Reserve University, lecturer at Northeast Ohio College of Pharmacy, and former practice owner of Veterinary Allergy & Dermatology, Inc. She is a former member-at-large on AVMA's Council on Biologicals and Therapeutics as chairman of the supplements and compounding committees. Along with publishing in human and veterinary journals, she authored the dermatology chapter in “Pharmacotherapeutics for Veterinary Dispensing”. Her interests include human-animal comparative dermatology and skin lipid research with publications in both areas.  Because of her pharmacist background of counseling patients, she is a strong believer in client education and maintains her website, www.purrfectpet.com, for clients to be educated with evidence-based information as well as an upcoming podcast "Speaking of Pets" The podcast is geared toward pet owners of allergic pets to provide them with accurate, evidence-based information.

Announcing Season Seven of Parenting Musically! Parenting Musically is supported by Case Western Reserve University. Season seven is co-hosted by Dr. Lisa Huisman Koops and Dr. George Blake, faculty members at Case Western Reserve University.

TransGenre (Cambridge UP, 2025) is a reconsideration of genre theory in long-form fiction through transgender minor literature in the US and Canada. Using four genre sites (the road novel, the mourning novel, the chosen family novel, and the archival novel), this Element considers how the minoritized becomes the minoritarian through deterritorializing generic conventions in fiction to its own ends. In so doing, TransGenre proposes narrative reading practices as strategies of the minor to subvert, transgress, and reappropriate the novel's genealogy and radical future prospects. A range of fiction published in the last decade is deployed as largely self-theorizing, generating its own epistemological, thematic, and formal innovations and possibilities, revealing cisheteronormative underpinnings of generic categories and turning them in on themselves. Aaron Hammes holds a PhD in English from the CUNY Graduate Center, and was most recently the Virginia and Walter Nord Postdoctoral Fellow in the Humanities at Case Western Reserve University. Dr. Hammes has published on sex work, transgender literature, and prison abolition in South Atlantic Review, Women's Studies Quarterly, the Routledge Handbook of Transgender Literature, Journal of Feminist Scholarship, and GLQ. Their first monograph, TransGenre, (Cambridge, 2025) is an exploration of genre theory and contemporary transgender minor literature. Atalia Israeli-Nevo is an anthropology PhD student at the University of Texas at Austin. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

TransGenre (Cambridge UP, 2025) is a reconsideration of genre theory in long-form fiction through transgender minor literature in the US and Canada. Using four genre sites (the road novel, the mourning novel, the chosen family novel, and the archival novel), this Element considers how the minoritized becomes the minoritarian through deterritorializing generic conventions in fiction to its own ends. In so doing, TransGenre proposes narrative reading practices as strategies of the minor to subvert, transgress, and reappropriate the novel's genealogy and radical future prospects. A range of fiction published in the last decade is deployed as largely self-theorizing, generating its own epistemological, thematic, and formal innovations and possibilities, revealing cisheteronormative underpinnings of generic categories and turning them in on themselves. Aaron Hammes holds a PhD in English from the CUNY Graduate Center, and was most recently the Virginia and Walter Nord Postdoctoral Fellow in the Humanities at Case Western Reserve University. Dr. Hammes has published on sex work, transgender literature, and prison abolition in South Atlantic Review, Women's Studies Quarterly, the Routledge Handbook of Transgender Literature, Journal of Feminist Scholarship, and GLQ. Their first monograph, TransGenre, (Cambridge, 2025) is an exploration of genre theory and contemporary transgender minor literature. Atalia Israeli-Nevo is an anthropology PhD student at the University of Texas at Austin. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/gender-studies

TransGenre (Cambridge UP, 2025) is a reconsideration of genre theory in long-form fiction through transgender minor literature in the US and Canada. Using four genre sites (the road novel, the mourning novel, the chosen family novel, and the archival novel), this Element considers how the minoritized becomes the minoritarian through deterritorializing generic conventions in fiction to its own ends. In so doing, TransGenre proposes narrative reading practices as strategies of the minor to subvert, transgress, and reappropriate the novel's genealogy and radical future prospects. A range of fiction published in the last decade is deployed as largely self-theorizing, generating its own epistemological, thematic, and formal innovations and possibilities, revealing cisheteronormative underpinnings of generic categories and turning them in on themselves. Aaron Hammes holds a PhD in English from the CUNY Graduate Center, and was most recently the Virginia and Walter Nord Postdoctoral Fellow in the Humanities at Case Western Reserve University. Dr. Hammes has published on sex work, transgender literature, and prison abolition in South Atlantic Review, Women's Studies Quarterly, the Routledge Handbook of Transgender Literature, Journal of Feminist Scholarship, and GLQ. Their first monograph, TransGenre, (Cambridge, 2025) is an exploration of genre theory and contemporary transgender minor literature. Atalia Israeli-Nevo is an anthropology PhD student at the University of Texas at Austin. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

Did you know that nearly one in three people with obesity may have fatty liver disease without even knowing it? In this episode, I talk about groundbreaking news in obesity and liver health, focusing on the FDA's recent approval of WeGovy to treat metabolic dysfunction associated steatohepatitis (MASH) with moderate to advanced fibrosis. I share a personal story about a friend who once struggled with fatigue, abnormal liver tests, and fatty liver disease, highlighting how limited treatment options used to be. I explain what MASH is, why it's so serious, and how common it is, especially among people with obesity and metabolic syndrome.  Furthermore, I dive into the ESSENCE trial, which showed that WeGovy not only improved liver inflammation and scarring but in some cases even reversed the disease, all while emphasizing that it works best when combined with lifestyle changes like healthy eating and regular activity.  Don't miss this episode where I break down the latest breakthrough in liver and weight loss care that could change your health journey!   Episode Highlights: FDA approval of WeGovy for treating MASH with fibrosis The ESSENCE trial results showing improvements in liver health Understanding what MASH is and why it's so common Importance of combining medication with lifestyle changes Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

This week as the negotiations for a Global Plastic Treaty fail in Geneva, Switzerland over a cap on plastic production, we look at the undue influence of the fossil fuel and plastic industries. False solutions to the climate crisis, and now the plastic pollution crisis, are part of an industry playbook to misinform the public and deflect from actual solutions. In the case of plastics, it's promoting plastic recycling that doesn't actually work. In our latest, we talk with researchers Davis Allen and Rebecca John to discuss industry strategies to undermine any progress on curbing plastic pollution. Bios//Rebecca John is a Research Fellow at the Climate Investigations Center. She is also a freelance journalist and award-winning documentary film maker. As a Producer and Director of the acclaimed “Extreme Oil” / “Curse of Oil” series for PBS /BBC her work was awarded a Cine Golden Eagle for News Analysis. Other award-winning and nominated series and films include “Churchill” for PBS & ITV, “The Secret World of Richard Nixon” for The History Channel/BBC and “Ambush In Mogadishu” for PBS Frontline/ BBC (winner of the Edward R. Murrow Overseas Press Club of America ‘Best Documentary on Foreign Affairs Award'). Davis Allen is a Senior Investigative Researcher at the Center for Climate Integrity, where he identifies and compiles evidence of the fossil fuel industry's historical — and ongoing — deception. Prior to joining CCI, Davis completed a PhD in History at Case Western Reserve University.-----------------------------------------------------------Outro- "Green and Red Blues" by MoodyLinks//+ "‘Maddening' Proof Plastics Industry Knew Recycling Was False Solution in 1974, New Document Shows" (https://bit.ly/45QWEHE)+ "The Fraud of Plastic" (https://bit.ly/4lt3Xd6)+ Plastic pollution talks fail as negotiators in Geneva reject draft treaties (https://bit.ly/45xljzF)

Research endowments and Trump administration.  EriK Jensen, Case Western Reserve University, Civitas Institute 1888 STANFORD MANSION

Research endowments and Trump administration.  EriK Jensen, Case Western Reserve University, Civitas Institute continued 1900